Phs 398 (rev. 9/04), biographical sketch format page

Principal Investigator/Program Director (Last, First, Middle): BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES.
Assistant Professor of Pharmacy Practice EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) University of Alberta, Edmonton, Alberta, Canada University of Alberta, Edmonton, Alberta, Canada University of Alberta, Edmonton, Alberta, Canada
Positions and Employment
05/1997 – 06/2001: Staff Pharmacist, Broadmoor Pharmacy, Sherwood Park, Alberta
01/1998 – 06/2001: Research Assistant, Institute of Health Economics, Edmonton, Alberta
11/2000 – 04/2001: Research Associate, Health Technology Assessment Unit, Alberta Heritage Foundation for
Medical Research, Edmonton, Alberta, Canada 09/2001 – 08/2008: Assistant Professor, Dept. of Pharmacy Practice, Univ. of Illinois at Chicago (UIC), 09/2003 – Present: Assistant Professor, Dept. of Pharmacy Administration, UIC, Chicago, IL. 09/2004 – Present: Research Associate, Center for Management of Complex Chronic Care (CMC3), VA 09/2005 – Present: Assistant Director, Center for Pharmacoeconomics Research, UIC, Chicago, IL.
Honors and Awards
1988, 1989: Certificate of Merit Award (University of Alberta)
1997: Institute of Pharmacoeconomics Graduate Assistantship Award (University of Alberta)
1999: J. Gordin Kaplan Travel Award (University of Alberta)
1999-00: Parke Davis Doctoral Fellowship in Pharmacy Practice Research
2000 - 2001: Alberta Heritage Foundation for Medical Research – Full-Time Studentship – Incentive Award,
Health Research
2000 – 2001: Rx&D – HRF (Health Research Foundation)/CIHR (Canadian Institutes of Health Research)
Graduate Research Scholarship in Pharmacy
2003: New Investigator Award, International Society for Quality of Life Research
2003: Best Overall Oral Presentation, International Society for Quality of Life Research Annual Conference
Peer-Reviewed Publications (since 2004)
Pickard AS
, Johnson JA, Feeny DH, Carriere KC, Shuaib A, Nasser AM. Agreement between self- and proxy
assessment in stroke: a comparison of generic HRQL measures. Stroke. 2004;35(2):607-12. Nutescu E, Pickard AS, Blackburn J, Schumock GT, Ansell J, Wittkowsky A. The implications of direct thrombin
inhibitors for anticoagulation clinics. Pharmacotherapy. 2004 Sept 24(9):1204-1212. Pickard AS, Topfer LA, Feeny DF. A structured review of studies on health-related quality of life and economic
evaluation in pediatric acute lymphoblastic leukemia. Journal of the National Cancer Institute Monographs. 2004 (33): 102-125. Pickard AS, Nau D, McKercher P, Schumock GT. The importation of prescription medications: the experiences,
opinions and intended behaviors of US community pharmacists. Journal of the American Pharmacists Association. 2004;44:666-672. Pickard AS, Johnson JA, Feeny DH. Responsiveness of the SF-36, HUI and EQ-5D in Stroke. Quality of Life Research.
PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Biographical Sketch Format Page
Principal Investigator/Program Director (Last, First, Middle): Pickard, AS, Wang Z, Walton SM, Lee TA. Do different preference-based algorithms for the SF-36 and SF-12 potentially
alter decision-making when applied to cost utility analysis? Health Outcomes and Quality of Life. 2005 Mar 4;3(1):11. Kramer KM, Bennett CL, Pickard AS, Lyons EA, Wolf MS, McKoy JM, Knight SJ. Patient preferences in prostate cancer:
a clinician's guide to understanding health utilities. Clin Prostate Cancer. 2005;4(1):15-23. Pickard AS, Knight S. A conceptual framework for understanding differences in proxy perspectives. Medical Care 2005
McCarthy M Jr, Chang CH, Pickard AS, Giobbie-Hurder A, Price DD, Jonasson O, Gibbs J, Fitzgibbons R, Neumayer L.
Visual analog scales for assessing surgical pain. J Am Coll Surg. 2005;201(2):245-52. McCarthy M Jr, Jonasson O, Chang CH, Pickard AS, Giobbie-Hurder A, Gibbs J, Edelman P, Fitzgibbons R, Neumayer
L. Assessment of patient functional status after surgery. J Am Coll Surg. 2005;201(2):171-8. Pickard AS, Hung SY, McKoy JM, Witt WP, Arseven A, Sharifi R, Wu Z, Knight SJ, McWilliams N, Schumock GT,
Bennett CL. Opportunities for disease state management in prostate cancer. Disease State Management. 2005;8(4):235-44. McKoy JM, Lyons EA, Obadina E, Carson K, Pickard AS, Schellhammer P, McLeod D, Boyd CE, McWilliams N, Sartor
O, Schumock GT, McCaffery K, Bennett CL. Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. Journal of Clinical Oncology. 2005;23(34):8894-905. Wolf MS, Fitzner KA, Powell EF, McCaffrey KR, Pickard AS, McKoy JM, Lindenberg J, Schumock GT, Carson KR,
Ferreira MR, Dolan NC, Bennett CL. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. Journal of Clinical Oncology. 2005;23(34):8877-83. Pickard AS, Dalal MR, Bushnell D. A comparison of depressive symptoms in stroke and primary care: applying Rasch
models to evaluate the CES-D scale. Value in Health 2006;9(1):59-64. Pickard AS, Dobrez D, Cella D. Empirically testing assumptions underlying the development of a set of societal weights
for the FACT-L. Pharmacoeconomics 2006;24(3):293-4. Wolf MS, Knight SJ, Lyons EA, Durazo-Arvizu R, Pickard AS, Arseven A, Arozullah A, Colella K, Ray P, Bennett CL.
Relation between literacy, race, and PSA level among men with newly diagnosed prostate cancer. Urology 2006; 68:89-93. Pickard AS, Hung S-Y. An update on evidence of clinical pharmacy services' impact on health-related quality of life.
Annals of Pharmacotherapy 2006;40(9):1623-34. Pickard AS. Towards supporting scholarship in research by clinical pharmacy faculty. Pharmacy Practice. Vol 4(4),
Krueger CD, West PM, Sargent MR, Lodolce AE, Pickard AS. Biphosphonate-induced osteonecrosis. Annals of
Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5
level version in cancer. Medical Care 2007;45(3): 259-263. Pickard AS, Wilke C, Lin HW, Lloyd A. EQ-5D health utilities in studies of cancer. Pharmacoeconomics. 2007;25(5):365-
Lee TA, Pickard AS, Bartle B, Weiss K. Osteoarthritis: a comorbid marker for longer life? Annals of Epidemiology.
Dobrez D, Cella D, Pickard AS, Lai JS, Nickolov A. Estimation of patient preference-based utility weights from the
functional assessment of cancer therapy - general. Value in Health. 2007;10(4):266-72. Lee TA, Pickard AS. Azelastine for allergic rhinitis: a meta-analysis. Pharmacotherapy. 2007;27(6):852-9.
Pickard AS, Kohlmann T, Janssen MF, Bonsel G, Rosenbloom S, Cella D. Evaluating Equivalency Between Response
Systems: Application of the Rasch Model to a 3-Level and 5-Level EQ-5D. Medical Care. 2007;45(9):812-819. Hung SY, Pickard AS, Witt WP, Lambert BL. Pain and depression in caregivers affected their perception of pain in stroke
patients. Journal of Clinical Epidemiology. 2007;60(9):963-70. Pickard AS, Neary M, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.
Health and Quality of Life Outcomes. 2007 Dec 21;5(1):70. Pickard AS, Schumock GT, Frye C, Becker R. A structured review of clopidogrel exposure prior to CABG surgery.
Pickard AS, Wilke CT, Jung E, Lee TA. Use of a preference-based measure of health (EQ-5D) in asthma and COPD.
Respiratory Medicine. 2008 April; 102:519-536. Lin HW, Pickard AS, Mahady GB, Popovich, NG. The development of a measure to assess pharmacists’ knowledge of
herbal and dietary supplements. In Press. American Journal of Pharmaceutical Education. PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle):
Ongoing Research Support

IIR 07-178 Lee (PI)
Veteran’s Affairs Management and control of coexisting chronic diseases in COPD patients The aims of this study are to: (1) describe the treatment and control of diabetes and hyperlipidemia among patients with COPD and these co-existing chronic conditions; (2) characterize factors associated with treatment and control (i.e. goal attainment) of diabetes and hyperlipidemia; (3) among patients with COPD, evaluate the association of management of diabetes and hyperlipidemia with short-term (e.g. hospitalization) and long-term (e.g. mortality) outcomes; (4) among patients with COPD, examine adverse consequences associated with management of diabetes and hyperlipidemia Role: Co-investigator 1R01XXXXXXXX Tulsky (PI) National Institute on disability and rehabilitation research Testing the Neuro-QOL in traumatic brain injury Item banks developed for the NeuroQol project funded by NINDS will be applied to TBI. For individuals in the severe TBI groups, the majority of assessments will be completed by proxy. Role: Consultant AHRQ – DEcIDE Task Order (Master agreement 2006-00304/submaster (TO#4) 2007-00894) Comparative effectiveness of anticholinergic medications in patients with chronic obstructive pulmonary disease (COPD) The aim of this study is to evaluate the incremental effectiveness of anticholinergic medications in terms of impact on mortality, exacerbations and hospitalizations in patients with COPD. Role: PI IN: 2007-03870 Pickard (PI) Northwestern University Assessment of the use and outcomes with antithrombotic therapy following orthopedic surgery in VA- Phase 1 The aim of this study is to examine the use of LMWHs in VA patients undergoing orthopedic surgeries and compare outcomes and healthcare utilitization between the different LMWHs. Role: PI IN: 2007-04899 Pickard (PI) Pfizer Estimation of a utility-based algorithm for the EORTC-QLQ. The aim of this study is to estimate a preference-based scoring algorithm for a descriptive system based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (QLQ30), a cancer specific measure of HRQL widely used to assess patient-reported quality of life outcomes in clinical trials. Role: PI PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle): Completed Research Support (past 3 years)

IN: 2007-02869 Pickard (PI)
Evanston Northwestern Healthcare A comparison of the impact of eleven types of cancer on quality of life The aim of this study is to compare the quality of life burden between 11 types of cancer across different dimensions of health-related quality of life according to the FACT and EQ-5D. Role: PI IN: 2007-00872 Jolly (PI) RUSH University Medical Center Health-related quality of life in patients with lupus This study aims to validate a modified version of a UK-based QOL measure for SLE in US patients. Role: Co-investigator (PI on UIC subcontract) HHSA290200500381, Task Order No. 1; TIN 37-6000511 (Lee: PI) AHRQ Outcomes of COPD Management The specific aims of this project are to: review datasets available to examine outcomes of COPD medication management; identify and prioritize key medication management issues in COPD; evaluate outcomes (COPD exacerbations, mortality) associated with inhaled corticosteroids (ICS) compared to concomitant use of ICS with long-acting beta agonists. Role: Co-investigator UIC IN: 2006-02332 Pickard (PI) EuroQol Foundation Rasch solution to EuroQol problems: exploring IRT Models to estimate label equivalency and a valuation crosswalk for the EQ-5D. The objectives of this study were: (1) to use Rasch models to compare the equivalency of the standard EQ-5D 3 level system to an experimental 5 level version, and (2) develop a crosswalk between the descriptive systems so that utility weights from the 3L can be applied to the 5L system . Role: PI 1R03 CA108395-01 Pickard (PI) National Cancer Institute/National Institutes of Health (NCI/NIH) Proxy perspectives on quality of life in prostate cancer. The aims of this study are to elicit proxy assessments of patients with prostate cancer in order: 1) To determine the extent of agreement between HRQL assessments performed by an informal caregiver from the perspective of the patient compared to their assessment of patient HRQL from the caregiver's own viewpoint; 2) To assess the extent of agreement between patient self-assessment in relation to two proxy assessed perspectives; and 3) To evaluate whether different proxy perspectives result in differences in HRQL assessment that are statistically significant and clinically meaningful. Role: PI 2005-1177 (UIC PAF) Witt (PI) American Cancer Society – Institutional Research Grant (Northwestern University) Biological and Self-Reported Measures of Psychological Stress among Informal Caregivers of Patients with Prostate Cancer: A Pilot Study. The aim of this pilot study is to determine the feasibility, performance, and comparability of stress biomarkers in caregivers of patients with prostate cancer as compared to caregiver-reported survey measures of psychological stress and how such measures are related to patient health outcomes. Role: Co-investigator PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Continuation Format Page


51_jco-1_cunningham:mise en page

V O L U M E 2 . N U M É R O 1 . J A N V / F É V 2 0 1 0Étude randomisée de phase III comparant gemcitabine à gemcitabine plus capécitabine chez des patients atteintsd’un cancer du pancréas de stade avancé David Cunningham, Ian Chau, Deborah D. Stocken, Juan W. Valle, David Smith, William Steward, (NHS) Foundation Trust, Londres et Surrey ; Peter G. Harper, Janet Dunn, Catrin Tudur-

Super long term grease + mos2

FICHE TECHNIQUE CRC SUPER LONG TERM GREASE + MoS2 Graisse super longue durée + MoS2 1. DESCRIPTION GENERALE Graisse au bisulfure de molybdène, pour conditions extrêmes. La Graisse Super Longue Durée + MoS2 est une graisse à base d’huile minérale, du type graisse au lithium, très performante, contenant du MoS2 (bisulfure de molybdène) et des additifs thermiquement stable

Copyright © 2010-2014 Medical Articles